HK1107774A1 - 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ; - Google Patents

5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ;

Info

Publication number
HK1107774A1
HK1107774A1 HK08101512.9A HK08101512A HK1107774A1 HK 1107774 A1 HK1107774 A1 HK 1107774A1 HK 08101512 A HK08101512 A HK 08101512A HK 1107774 A1 HK1107774 A1 HK 1107774A1
Authority
HK
Hong Kong
Prior art keywords
benzyloxyphenylthio
imidazolidin
fur
dione
inhibitors
Prior art date
Application number
HK08101512.9A
Other languages
English (en)
Inventor
Fude Yang
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Publication of HK1107774A1 publication Critical patent/HK1107774A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK08101512.9A 2004-08-19 2008-02-11 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ; HK1107774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (1)

Publication Number Publication Date
HK1107774A1 true HK1107774A1 (en) 2008-04-18

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101512.9A HK1107774A1 (en) 2004-08-19 2008-02-11 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ;

Country Status (17)

Country Link
US (1) US7179831B2 (ja)
EP (1) EP1789036B1 (ja)
JP (1) JP5042833B2 (ja)
KR (1) KR101197325B1 (ja)
CN (1) CN101014338B (ja)
AT (1) ATE508744T1 (ja)
AU (1) AU2005277432B2 (ja)
BR (1) BRPI0514470B8 (ja)
CA (1) CA2577430C (ja)
DK (1) DK1789036T3 (ja)
ES (1) ES2364068T3 (ja)
HK (1) HK1107774A1 (ja)
MX (1) MX2007001940A (ja)
NZ (1) NZ553258A (ja)
RU (1) RU2391339C2 (ja)
SI (1) SI1789036T1 (ja)
WO (1) WO2006023562A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
NZ751777A (en) * 2016-08-19 2020-08-28 Foresee Pharmaceuticals Co Ltd Pharmaceutical composition and methods of uses
CA3036642C (en) * 2016-09-23 2024-04-09 Kaken Pharmaceutical Co., Ltd. Method for producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidin-2,4-dione and intermediate for producing same
PT3793995T (pt) * 2018-05-15 2024-05-02 Foresee Pharmaceuticals Usa Inc Inibidores de metaloproteinases de matriz (mmp) e métodos de uso dos mesmos
BR112022009131A2 (pt) 2019-11-14 2022-07-26 Foresee Pharmaceuticals Co Ltd Inibidores de metaloproteinase de matriz (mmp) e métodos de uso dos mesmos
IL308793A (en) * 2021-06-08 2024-01-01 Foresee Pharmaceuticals Co Ltd Safe delivery of an MMP-12 inhibitor
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7041693B2 (en) * 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)

Also Published As

Publication number Publication date
RU2391339C2 (ru) 2010-06-10
EP1789036B1 (en) 2011-05-11
BRPI0514470B1 (pt) 2021-01-05
DK1789036T3 (da) 2011-06-27
WO2006023562A3 (en) 2006-04-20
KR20070045330A (ko) 2007-05-02
JP5042833B2 (ja) 2012-10-03
CN101014338B (zh) 2010-06-16
ATE508744T1 (de) 2011-05-15
AU2005277432B2 (en) 2011-11-24
WO2006023562B1 (en) 2006-06-22
CA2577430C (en) 2010-12-07
BRPI0514470A (pt) 2008-06-10
KR101197325B1 (ko) 2012-11-05
ES2364068T3 (es) 2011-08-24
RU2007105822A (ru) 2008-09-27
NZ553258A (en) 2011-02-25
SI1789036T1 (sl) 2011-09-30
CN101014338A (zh) 2007-08-08
EP1789036A2 (en) 2007-05-30
WO2006023562A2 (en) 2006-03-02
AU2005277432A1 (en) 2006-03-02
CA2577430A1 (en) 2006-03-02
MX2007001940A (es) 2007-07-24
EP1789036A4 (en) 2008-08-27
JP2008510701A (ja) 2008-04-10
US20060041000A1 (en) 2006-02-23
BRPI0514470B8 (pt) 2021-07-20
US7179831B2 (en) 2007-02-20

Similar Documents

Publication Publication Date Title
HK1107774A1 (en) 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase ;
TW200735865A (en) Compositions of an anticonvulsant and methods of using the same for reversing weight gain
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
NO20081636L (no) FAP - inhibitorer
TW200715969A (en) Fungicidal active-compound combination
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
FR2835186B1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE602007011664D1 (de) Mykotoxin reduzierende zusammensetzung
WO2008005145A3 (en) Controlling memory parameters
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
IL190730A0 (en) Potassium channel inhibitors
UA98608C2 (en) Benzofused five-membered heterocycles and use thereof
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
AU2003215158A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200813